Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
Court rejects brand‑maker’s inducement claim against a generic drug maker, making it harder for drug companies to sue generics over labels, websites, and press releases and protecting skinny‑labeled generics.